BioAtla Revenue and Competitors
Estimated Revenue & Valuation
- BioAtla's estimated annual revenue is currently $10.2M per year.
- BioAtla's estimated revenue per employee is $150,441
- BioAtla's total funding is $261.5M.
Employee Data
- BioAtla has 68 Employees.
- BioAtla grew their employee count by 13% last year.
BioAtla's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Development & Operations | Reveal Email/Phone |
2 | Chief Intellectual Property & Strategy, Cofounder | Reveal Email/Phone |
3 | Head Regulatory Affairs | Reveal Email/Phone |
4 | VP Research/Development Asia | Reveal Email/Phone |
5 | VP CMC | Reveal Email/Phone |
6 | VP Intellectual Property & Contracts | Reveal Email/Phone |
7 | VP, Human Resources | Reveal Email/Phone |
8 | CMC Asociate Director | Reveal Email/Phone |
9 | Executive Director, Drug Discovery and Assay Development | Reveal Email/Phone |
10 | Director, Clinical Data Management | Reveal Email/Phone |
BioAtla Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is BioAtla?
BioAtla is a protein therapeutic company that uses discovery and evolution to develop safer and more potent drugs for the treatment of cancer. The culmination of our discovery and evolution expertise and more than 150 issued patents and patent applications is our Conditionally Active Biologics (CAB) platform, whereby monoclonal antibodies or other biologics can be engineered for selective conditional activation, for example preferential binding under the unique conditions of the tumor microenvironment. This improvement in tumor selectivity helps address the issue of on-target toxicity and improve therapeutic index. BioAtla is applying these technologies in our own pipeline and in partnerships to ultimately deliver better immunotherapies for cancer.
keywords:N/A
$261.5M
Total Funding
68
Number of Employees
$10.2M
Revenue (est)
13%
Employee Growth %
N/A
Valuation
N/A
Accelerator
BioAtla News
Analysts expect BioAtla to post earnings of ($0.69) per share for the quarter. Investors interested in registering for the company's conference...
Given BioAtla's stronger consensus rating and higher probable upside, analysts plainly believe BioAtla is more favorable than Mesoblast.
About BioAtla, Inc. BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China...
SAN DIEGO, Nov. 15, 2021 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced financial results for the third quarter of 2021 and provided an update on ...
SAN DIEGO, Sept. 29, 2021 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that it has entered into stock purchase agreements with a group of instit ...
Other Companies in San Diego
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $9.2M | 68 | 10% | N/A |
#2 | $11M | 68 | N/A | N/A |
#3 | $14M | 68 | 6% | N/A |
#4 | $13.5M | 68 | 8% | N/A |
#5 | $16.5M | 68 | 8% | N/A |